Status:

NOT_YET_RECRUITING

Semaglutide Treatment in Type 1 Diabetes

Lead Sponsor:

Nordsjaellands Hospital

Collaborating Sponsors:

Steno Diabetes Center Copenhagen

Steno Diabetes Center Odense

Conditions:

Obesity in Diabetes

Obesity/Therapy

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hyp...

Detailed Description

This is a multicentre, randomised, double-blinded, placebo-controlled and investigator-initiated trial aimed to investigate the efficacy of semaglutide in patients with Type 1 Diabetes. Patients from...

Eligibility Criteria

Inclusion

  • Type 1 Diabetes for more than 3 years
  • BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis

Exclusion

  • Treated with GLP1-RAs within last 6 months
  • Known intolerance for semaglutide
  • Other forms of diabetes
  • Pregnant or nursing women
  • Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives
  • Liver disease with elevated plasma alanine aminotransferase (ALT) \> five times and plasma aspartate aminotransferase (AST) \> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)
  • Acute or chronic pancreatitis
  • Cancer, unless in complete remission for \> 5 years or unless basocellular carcinomas
  • History of thyroid adenoma or carcinoma
  • Alcohol/drug abuse
  • Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation
  • Receipt of an investigational drug within 30 days prior to visit 0 / Simultaneous participation in any other clinical intervention trial

Key Trial Info

Start Date :

October 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

122 Patients enrolled

Trial Details

Trial ID

NCT06909006

Start Date

October 1 2025

End Date

June 1 2028

Last Update

August 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nordsjaellands Hospital

Hillerød, Denmark, Denmark, 3400